Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
FDA DecisionapprovedLISRAYAPositive
AI Analysis
Summary
Roivant announced FDA approval of LISRAYA (brepocitinib) for adults with dermatomyositis, with the drug now available in the United States. This represents a major milestone for the company's pipeline.
Outcome Details
FDA approval granted for LISRAYA (brepocitinib) for adults with dermatomyositis
Importance:9/10
Sentiment:
0.95
FDA approvaldermatologyautoimmune diseaserare diseasecommercial launch
Related Companies
Read the original article
Published by yahoo_finance on August 27, 2026 7:29 PM